Ranbaxy agrees to pay $39 mn to settle cases linked to Texas healthcare programme
The payments will be made in tranches through August 2015, Ranbaxy informed the BSE on Thursday.<br />
Mumbai: Generic drugmaker Ranbaxy Laboratories Ltd said it had agreed to pay $39.75 million to settle litigations concerning its participation in Texas Medicaid, the US federal-state healthcare program for the poor.
The payments will be made in tranches through August 2015, Ranbaxy informed the BSE on Thursday.
"The claims at issue related exclusively to the manner in which Ranbaxy has historically reported pricing data to Texas Medicaid for certain of its drugs," the company said in the statement.
Ranbaxy shares were up 0.7 percent at 602.10 rupees at 9:47 a.m. in Mumbai, while the broader Nifty was up 0.14 percent on Thursday.
A statement from US Soccer said CONCACAF had opened an investigation into the alleged incident, which occurred at Tuesday's game between the United States and Nicaragua in Guatemala City, won 4-2 by the United States.
The new travel restrictions have been imposed for an indefinite period and will require another presidential proclamation to be ended
COVID-19 vaccination: Third phase to inoculate 18 to 45 sees staggered start in Gujarat, UP, Maharashtra, Tamil Nadu
The vaccination drive failed to take off in Delhi, West Bengal, Assam, and Karnataka on Saturday while Odisha organized a symbolic inoculation drive